Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital

Stoke Therapeutics (NASDAQ:STOK) had its price objective upped by analysts at Chardan Capital from $24.00 to $35.00 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price objective suggests a potential upside of 13.27% from the stock’s previous close.

A number of other equities analysts also recently commented on STOK. Needham & Company LLC lifted their target price on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a report on Monday, December 15th. HC Wainwright lifted their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Finally, Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.70.

Stoke Therapeutics Stock Down 2.6%

Shares of NASDAQ:STOK opened at $30.90 on Monday. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $38.69. The stock has a market cap of $1.77 billion, a P/E ratio of 46.12 and a beta of 1.10. The business has a fifty day moving average of $29.94 and a two-hundred day moving average of $23.03.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The company had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. On average, equities analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 5,931 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total value of $152,545.32. Following the completion of the transaction, the insider owned 7,195 shares in the company, valued at approximately $185,055.40. This trade represents a 45.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 25,000 shares of Stoke Therapeutics stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total value of $750,000.00. Following the transaction, the director owned 49,124 shares in the company, valued at approximately $1,473,720. This trade represents a 33.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 129,705 shares of company stock worth $3,820,910. 9.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC bought a new stake in Stoke Therapeutics in the second quarter valued at about $7,489,000. Wellington Management Group LLP increased its position in shares of Stoke Therapeutics by 438.2% during the third quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after acquiring an additional 600,687 shares in the last quarter. Polar Capital Holdings Plc increased its stake in Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after buying an additional 439,824 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Stoke Therapeutics by 67.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 900,272 shares of the company’s stock worth $21,156,000 after purchasing an additional 362,299 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Stoke Therapeutics during the first quarter worth approximately $2,376,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.